Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Arbutus Biopharma Corp.
Headquarters: Warminster, PA, United States of America
Website: http://arbutusbio.com
Year Founded: 2005
Status: Public
Industry Sector: HealthTechnology
CEO: Lindsay Androski, CFA, MBA
Number Of Employees: 44
Enterprise Value: $490,436,018
PE Ratio: -8.56
Exchange/Ticker 1: NASDAQ:ABUS
Exchange/Ticker 2: N/A
Latest Market Cap: $672,094,784
BioCentury | Feb 26, 2025
Management Tracks
Lindsay Androski named CEO of Arbutus
Plus: CMO Maria Koehler steps down at Repare, and updates from Isomab, Crescent, Ottimo and Senti Bio
BioCentury | Oct 29, 2024
Management Tracks
Biogen names new CFO, CMO
Plus management updates at Ottimo, Genascence, Pll, Nabsys 2.0 and Arbutus
BioCentury | Aug 15, 2024
Finance
No sleep for the biotech bear: Restructurings abound in August
At least 20 companies have trimmed pipelines, cut staff or otherwise re-jiggered strategies in past two weeks to extend runway
BioCentury | Jul 12, 2023
Management Tracks
Eisai’s Cheung, head of U.S. and Leqembi lead, retiring
Plus: Paterson becomes CEO of Verastem, and updates from
BioCentury | Oct 1, 2022
Management Tracks
Neurocrine’s Delaet now chief regulatory officer
Plus Picchio to leave Arbutus and Pharvaris promotes Deschoolmeester
BioCentury | Dec 14, 2021
Product Development
Dec. 13 Quick Takes: Bellus headed for Phase III in chronic cough
Plus: Veru’s Entadfi approved, Brii asset on hold and updates from Arbutus, BrainStorm and Vaccitech
BioCentury | Aug 12, 2021
Emerging Company Profile
Bluejay: combining HBV therapies to reach a functional cure
Emerging Company Profile: Led by Keting Chu, Bluejay is advancing HBV assets in-licensed from Novartis
BioCentury | Mar 19, 2021
Product Development
Pandemic response ushers in new era of biopharma data sharing: Guest Commentary
The COVID R&D Alliance tells the story of a pharma data sharing initiative that could extend beyond COVID-19
BioCentury | Feb 27, 2021
Translation in Brief
A $53M UC Berkeley-UCSF-Genentech-Roche collaboration on brain diseases; plus Selecta, JDRF-Harvard Stem Cell Institute, Tissue Dynamics and more
BioCentury’s roundup of translational news
BioCentury | Jul 24, 2020
Politics, Policy & Law
Moderna says commercial path remains clear despite unfavorable patent ruling
Items per page:
1 - 10 of 76